Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide Mesilate as Add-on to Levodopa in Parkinson's Disease
NCT05312632Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of safinamide in Parkinson's disease (PD), sponsored by Eisai Co., Ltd. Primary endpoints: Change From Baseline in Daily OFF Time at 18 weeks and Change From Baseline in Parkinson's Disease Questionnaire-39 at 18 weeks. Started Apr 2022; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05312632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312632.